Taficita
✅ HIV treatment
✅ Verlaagt de virale lading
✅ Versterkt het immuunsysteem
✅ Lowers transmission risk
✅ Improves life expectancy
Taficita contains Emtricitabine and Tenofovir.
✓ Medisch beoordeeld door Morgan Ellis — Apotheekonderzoeker · 8 jaar ervaring · Laatst beoordeeld: mei 2026
⚡ Quick Answer — What is Taficita?
Taficita bevat tenofovir alafenamide 25 mg + emtricitabine 200 mg and is used for HIV pre-exposure prophylaxis (PrEP) in HIV-negative MSM and transgender women at substantial risk. TAF-based PrEP is approved for HIV prevention in cisgender men who have sex with men (MSM) and transgender women (DISCOVER trial, 2019) — not for cisgender women, where trial evidence is insufficient. Daily dosing only; non-inferior to TDF/FTC with substantially better renal and bone safety (DISCOVER trial). Manufactured by Emcure Pharmaceuticals. Specialist-supervised; requires HIV-negative status confirmed before starting and every 3 months on therapy.
📦 Elke bestelling is gedekt door onze Reshipment Assurance Policy — als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.
Waarom bestellen bij MedsBase
Wat Is Acivir 200 DT? Reshipment Assurance Policy.
Taficita is een daily HIV pre-exposure prophylaxis (PrEP) tablet combining tenofovir alafenamide (TAF) 25 mg en emtricitabine (FTC) 200 mg — the same fixed-dose combination that makes up the brand-name Descovy® originally developed by Gilead Sciences. Taficita is Emcure Pharmaceuticals’ tenofovir alafenamide + emtricitabine tablet — a Descovy-generic positioned for HIV-negative MSM and transgender women who want PrEP with the improved renal and bone safety profile of the TAF prodrug over the older TDF-based combinations.
TAF is a newer prodrug form of tenofovir developed specifically to solve the renal and bone side effects of the older tenofovir disoproxil fumarate (TDF). By delivering tenofovir selectively to target cells, TAF achieves equivalent antiviral activity at approximately one-tenth the plasma tenofovir exposure — meaning much lower kidney and bone toxicity over years of daily use.
What Is Taficita?
Taficita is a fixed-dose combination tablet of two nucleoside/nucleotide reverse transcriptase inhibitors:
- Tenofovir alafenamide (TAF) 25 mg — a prodrug of tenofovir that is activated primarily inside target cells (HIV-infected or HIV-susceptible cells). Delivers equivalent intracellular drug levels to TDF while keeping plasma tenofovir ~90% lower
- Emtricitabine (FTC) 200 mg — the same cytidine analogue reverse transcriptase inhibitor used in TDF/FTC regimens, with a complementary resistance profile to TAF
Used as PrEP, Taficita pre-loads HIV-susceptible cells with reverse-transcriptase inhibitor so that any incoming virus from a sexual exposure cannot complete its reverse transcription step and therefore cannot establish chronic infection.
Clinical equivalence: Taficita and branded Descovy contain identical active ingredients (TAF 25 mg + FTC 200 mg) and are manufactured to bioequivalence standards set by drug-regulatory bodies. The clinical evidence from DISCOVER (the TAF/FTC PrEP trial) applies equally to all manufacturers of this fixed-dose combination.
TAF vs TDF — Why Would I Choose This?
| Consideration | TAF/FTC (this product) | TDF/FTC (Tenvir EM, etc.) |
|---|---|---|
| Renal safety | Significantly better — ~90% lower plasma tenofovir exposure. Preferred for eGFR 30–59 mL/min (where TDF is contraindicated) | Small decline in eGFR with long-term use; contraindicated below eGFR 60 mL/min |
| Bone mineral density | Clinically meaningful advantage — no significant BMD decline observed in DISCOVER. Preferred for osteopenia/osteoporosis | Small but real BMD decline, particularly in the first 2 years |
| Approved PrEP populations | Cisgender MSM and transgender women only (based on DISCOVER trial design). Not FDA-approved for cisgender women — trial did not include them | All at-risk populations — cis-men, cis-women, trans people, injection drug users (iPrEx, PROUD, Partners PrEP, HPTN 084) |
| Dosing schedules | Daily only. On-demand 2-1-1 is not validated for TAF | Daily, or on-demand 2-1-1 for cis-MSM (IPERGAY protocol) |
| Kosten | Typically higher than TDF/FTC generics | Lowest-cost PrEP option |
| Weight changes | Small weight gain observed (~1–2 kg over a year; mechanism not fully understood) | Weight-neutral or slight weight loss |
| Lipid profile | Modestly raises LDL and total cholesterol | Mildly lowers LDL (via TDF’s independent lipid effect) |
Decision rule of thumb: if you have normal renal function, no bone-density concerns, and you want the widest approved indication set (and lowest cost), TDF/FTC (Tenvir EM) is first-line. If you have reduced eGFR (30–59), existing osteopenia/osteoporosis, or are a cis-MSM or transgender woman wanting the safer long-term profile, Taficita is the better fit.
How Taficita Works as PrEP
Once swallowed, TAF is stable in plasma (unlike TDF which is cleaved in blood to tenofovir) and is taken up selectively by lymphocytes, gut mucosa, and other HIV-target cells. Inside these cells, TAF is converted by cellular enzymes to the active metabolite tenofovir diphosphate, which competes with natural nucleotides at HIV reverse transcriptase and terminates DNA chain elongation.
Key pharmacokinetic points affecting protection:
- Rectal tissue concentration reaches protective levels quickly on daily dosing — DISCOVER’s exposure data showed robust protection in MSM taking ≥4 doses per week
- Cervicovaginal and injection exposure — TAF/FTC is NOT FDA-approved for cisgender women. The DISCOVER trial design did not include cis-women, so efficacy for vaginal sex and injection-drug exposure has not been formally demonstrated. Cis-women seeking PrEP should use TDF/FTC (which has strong Partners PrEP and HPTN 084 data)
- Tenofovir diphosphate (intracellular) half-life is long enough to tolerate an occasional missed dose, but skipping multiple doses per week meaningfully reduces protection
- Tail cover after last exposure: continue dosing for at least 28 days after the last potential HIV exposure to cover the incubation window
Before Starting PrEP — Mandatory Tests
The pre-start testing requirements for TAF/FTC PrEP are identical to TDF/FTC:
| Test | Why It Matters | Timing |
|---|---|---|
| HIV test (4th-generation antigen/antibody or HIV RNA) | Must be confirmed negative. Starting PrEP while unknowingly HIV-positive drives resistance (M184V, K65R) that compromises future HIV treatment options | Within 7 days of starting |
| Hepatitis B-oppervlakteantigeen (HBsAg) | TAF/FTC also treats HBV. In HBV-positive patients, discontinuing PrEP can cause a severe hepatitis flare — manage with hepatology input | Baseline |
| Nierfunctie (creatinine, eGFR) | TAF is safer on kidneys than TDF, but still requires eGFR ≥30 mL/min. Below that, safety data are limited | Baseline, then every 12 months (less frequent than with TDF) |
| STI screen (syphilis, chlamydia, gonorrhoea) | PrEP prevents HIV, not other STIs. Baseline + quarterly screening is standard of care | Baseline, every 3 months |
| Lipid panel (baseline for comparison) | TAF/FTC modestly raises LDL and total cholesterol. Worth a baseline so any changes can be interpreted | Baseline, then as clinically indicated |
Ongoing monitoring: HIV test every 3 months. STI screen every 3 months. Renal function at least annually. Lipid panel as clinically indicated. HBV status need not be re-tested if negative at baseline unless new risk factors arise.
Dosering
Daily only. One tablet taken at the same time each day. Unlike TDF/FTC, the on-demand 2-1-1 (IPERGAY) protocol is NOT validated for TAF/FTC — TAF’s distinct cellular pharmacokinetics were not studied in on-demand dosing trials, and there is no evidence base to support it. If you want the flexibility of on-demand dosing, use TDF/FTC (Tenvir EM) instead.
If you miss a dose: take it as soon as you remember within 24 hours. If more than 24 hours have passed, skip the missed dose and continue with the next scheduled one — do not double up.
Timing with food: can be taken with or without food. If nausea is a problem in the first weeks, taking with food helps.
Bijwerkingen
TAF/FTC is generally better tolerated than TDF/FTC, especially in the first weeks. Most side effects occur in the “start-up” 2–4 weeks and resolve with continued use.
| Ernst | Bijwerking |
|---|---|
| Common, transient | Mild nausea, diarrhoea, abdominal discomfort, headache. Generally milder than with TDF |
| Less common | Weight gain (approximately 1–2 kg over 1 year), modestly raised LDL and total cholesterol, dizziness, insomnia, rash |
| Zeldzaam maar ernstig | Lactic acidosis, severe liver enzyme elevation, hepatic steatosis, severe allergic reaction. Seek urgent medical attention for severe fatigue, unexplained muscle pain, persistent nausea, or jaundice |
| HBV-specific | Stopping TAF/FTC abruptly in HBV-positive patients can trigger acute hepatitis flare — potentially life-threatening. HBV-positive patients on PrEP must not stop suddenly without hepatologist involvement |
Compared to TDF/FTC: lower renal toxicity, lower bone mineral density decline, slightly higher weight and lipid effects, similar GI tolerability, identical HBV considerations.
Contraindications and Precautions
- Confirmed HIV-positive status — TAF/FTC is a 2-drug regimen that is sub-therapeutic for HIV treatment; using it selects for resistance mutations that compromise future treatment options
- eGFR below 30 mL/min — safety and efficacy data are limited; specialist input recommended
- Acute hepatitis — use caution and consult a hepatologist
- Borstvoeding — tenofovir is secreted in breast milk. TAF secretion is lower than TDF but risk/benefit review with a clinician is advised
- Women seeking PrEP for vaginal/frontal sex exposure — use TDF/FTC instead; TAF/FTC does not have regulatory approval or trial data for this population
Geneesmiddelinteracties
- Rifampin, rifabutin, carbamazepine, phenytoin, St John’s wort — strong inducers of the enzymes that activate TAF. Gecontra-indiceerd or requires dose adjustment; consult a clinician
- Nefrotoxische geneesmiddelen (aminoglycosides, amphotericin B, cidofovir, IV pentamidine) — still worth avoiding despite TAF’s better renal profile
- Didanosine (ddI) — avoid combining (historic co-toxicity concerns from TDF era, limited data for TAF but caution warranted)
- HIV post-exposure prophylaxis (PEP) regimens — if PEP is needed after high-risk exposure, manage together with an HIV specialist
How to Take Taficita — Practical Guidance
- Swallow the tablet whole with water, at the same time each day. Missing more than 1–2 doses per week meaningfully reduces protection
- Kan met of zonder voedsel worden ingenomen
- If a dose is missed and remembered within 24 hours, take it as soon as remembered; otherwise skip the missed dose
- Do niet stop PrEP suddenly if you are HBV-positive without clinician involvement
- Continue for at least 28 days after your last sexual exposure (2-dose tail) to cover the incubation window
- Return quarterly for HIV and STI testing; yearly for renal and lipid panel
Opslag
- Store below 30°C in a cool, dry place
- Keep in the original bottle or blister packaging until use
- Niet gebruiken na de vervaldatum die op de verpakking staat vermeld
- Buiten bereik van kinderen en huisdieren houden
Related PrEP Options on MedsBase
- Tenvir EM — Cipla’s TDF/FTC (generic Truvada). Our most-referenced PrEP page. Approved for all at-risk populations including cis-women
- Ricovir EM — Mylan/Viatris TDF/FTC alternative
- Tavin EM — Emcure TDF/FTC alternative
- Tenof EM — Hetero TDF/FTC alternative
- SOA-beschermingspakket — TDF/FTC + doxycycline (DoxyPEP) + azithromycin stack for broader sexual-health coverage
See also the HIV-medicatie en Seksuele gezondheid categories.
Veelgestelde vragen
Is Taficita the same as Descovy?
Clinically equivalent. Taficita contains exactly the same active ingredients as Descovy® (tenofovir alafenamide 25 mg + emtricitabine 200 mg) and is produced to pharmaceutical bioequivalence standards. The clinical evidence from the DISCOVER trial that supports TAF/FTC PrEP applies to all bioequivalent generics of this fixed-dose combination.
Can I use Taficita if I’m a cisgender woman?
Not as first-line. TAF/FTC is approved for PrEP only in cisgender MSM and transgender women because the DISCOVER trial did not enroll cisgender women. If you are a cisgender woman seeking PrEP, TDF/FTC (for example Tenvir EM) has strong evidence from Partners PrEP and HPTN 084 and is the correct first choice.
How effective is Taficita compared to TDF/FTC?
The DISCOVER trial (2019) showed TAF/FTC is non-inferior to TDF/FTC for HIV prevention in MSM and transgender women, with better renal and bone safety. Both regimens reduce HIV risk by >99% with high adherence.
Why would I pay more for Taficita versus a TDF generic?
Two main reasons: (1) significantly lower impact on kidney function and bone density, which matters if you plan to be on PrEP for many years or have existing risk factors; (2) you have baseline renal impairment (eGFR 30–59 mL/min) where TDF is contraindicated. For otherwise healthy users without these considerations, TDF/FTC is equally effective and cheaper.
Can I take Taficita on an “as-needed” schedule?
Nee. The 2-1-1 (on-demand) protocol is not validated for TAF. Only daily dosing is supported by evidence. If you want on-demand dosing and you are cisgender MSM, use TDF/FTC instead — IPERGAY and Prevenir data support 2-1-1 for TDF/FTC.
What about weight gain?
TAF/FTC is associated with small weight gains in studies (~1–2 kg over a year). The mechanism isn’t fully understood. For most users this is clinically insignificant, but it is a real difference versus TDF/FTC, which tends to be weight-neutral.
Do I still need condoms?
Yes. PrEP prevents HIV only. Condoms reduce the risk of other STIs (chlamydia, gonorrhoea, syphilis, herpes, HPV, mpox) and pregnancy. PrEP + condoms + quarterly STI screening + vaccinations (HPV, HepA, HepB if not immune) together form a complete sexual-health strategy.
What happens if I stop Taficita?
If you are HIV-negative and HBV-negative, you can stop safely after a 28-day tail following your last HIV exposure. If you are HBV-positive, do not stop without clinician involvement — abrupt TAF discontinuation in chronic HBV can trigger an acute hepatitis flare.
Can I switch from TDF/FTC to Taficita?
Yes, and this is a common clinical decision when renal function declines, bone density concerns arise, or long-term safety is prioritised. Switching should be managed by a clinician with appropriate follow-up testing.
Is Taficita available without a prescription?
Nee. PrEP is a specialist-supervised regimen that requires baseline HIV-negative status confirmation, kidney-function and HBV testing, and follow-up every 3 months. Do not start PrEP without clinician confirmation of HIV-negative status and baseline safety tests.
Taficita (TAF/FTC) covers HIV PrEP only; for the layered PrEP + bacterial-STI regimen see our PrEP Starter Pack (Tenvir-EM + doxycycline 100 mg) — the established TDF/FTC PrEP combo bundled with doxy-PEP coverage at a lower combined price.
Individuals starting PrEP who cannot access TAF-based Taficita may consider Tenvir EM (tenofovir disoproxil fumarate 300 mg + emtricitabine 200 mg) as the clinically equivalent TDF/FTC alternative, sharing the same once-daily dosing schedule and equivalent long-term PrEP efficacy data.
Prescribers reviewing older TDF-based backbone options alongside Taficita (tenofovir alafenamide 25 mg + emtricitabine 200 mg) often reference Avonza (TDF / lamivudine / efavirenz) as the established prior-line benchmark when evaluating cost-accessibility in resource-limited settings.
Andere Seksuele Gezondheidsmedicijnen
- Tenvir EM (TDF/FTC 300+200 mg)
- Ricovir EM (TDF/FTC 300+200 mg)
- Tenof EM (TDF/FTC 300+200 mg)
- Tavin EM (TDF/FTC 300+200 mg)
- SOA-beschermingspakket
Medische disclaimer: De informatie op deze pagina is alleen voor educatieve doeleinden en vervangt geen medisch advies. Raadpleeg altijd een gekwalificeerde arts voordat u begint, stopt of wijzigt met medicatie.
Meer opties in PrEP-medicatie (Pre-exposure Profylaxe)
Gerangschikt op recente bestelvolumes van MedsBase — wat andere klanten in deze categorie kiezen.
| Sterkte | 200/25 mg |
|---|---|
| Hoeveelheid | 1 Fles/s, 2 Flessen/s, 3 Flessen/s, 6 Flessen/s |
Vragen & antwoorden
Taficita
Gerelateerde producten
